According to CRI’s market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year. The main reason is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Meropenem in China is 2% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Meropenem will have a recovery growth from 2021 to 2025. In addition, the strict limits on the usage of antibiotic drugs and the emergence of drug resistance have driven the demand for more effective antibacterial drugs. Therefore, Meropenem, as a new generation of antibacterial drugs, has the potential to expand its sales in the future.

Topics Covered:
-The impact of COVID-19 on China’s Meropenem market
– Sales value and volume of China’s Meropenem 2016-2020
– Competitive landscape of China’s Meropenem market
– Prices of Meropenem in China
– Prices of Meropenem in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Meropenem market
– Prospect of China’s Meropenem market from 2021 to 2025

The post Investigation Report on China’s Meropenem Market 2021-2025 first appeared on CRI Report.

Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma.

Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.

According to CRI’s market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab’s sales values in China is 108.7 in 2018 to 2020%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Nivolumab will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. Currently, Nivolumab has three approved indications, including non-small cell lung cancer, head and neck squamous cell carcinoma, and gastric adenocarcinoma and gastroesophageal junction cancer.

Its fourth indication application is at the approval stage. As the number of approved indications increases, the sales will continue to grow. On the other hand, the usage rate of Nivolumab was lower than that of other PD-1 products that have been included in the national medical insurance catalog. If the medical insurance negotiation for Nivolumab succeeds, the price adjustment can reduce the burden on patients, which will increase its usage rate.

Topics Covered:
-The impact of COVID-19 on China’s Nivolumab market
– Sales value and volume of China’s Nivolumab 2016-2020
– Competitive landscape of China’s Nivolumab market
– Prices of Nivolumab in China
– Prices of Nivolumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Nivolumab market
– Prospect of China’s Nivolumab market from 2021 to 2025

The post Investigation Report on China’s Nivolumab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Oseltamivir in the Chinese market has been increasing since 2016. The growth rate in 2019 reached 97%, which is the highest among those years. The main reason is that the number of reported influenza cases that year increased by 350% compared with it in 2018. In 2020, the sales value of Oseltamivir in China was approximately CNY351 million, which is dropped by nearly 60% Year on Year. The sharp decrease is because the home quarantine during the COVID-19 epidemic reduced the number of influenza cases. The CAGR of sales values of Oseltamivir in China is 14.8% in 2016 to 2020.

CRI analyzes that the sales of Oseltamivir will increase from 2021 to 2025 due to the increased likelihood of influenza virus infection in the future.

Topics Covered:
-The impact of COVID-19 on China’s Oseltamivir market
– Sales value and volume of China’s Oseltamivir 2016-2020
– Competitive landscape of China’s Oseltamivir market
– Prices of Oseltamivir in China
– Prices of Oseltamivir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Oseltamivir market
– Prospect of China’s Oseltamivir market from 2021 to 2025

The post Investigation Report on China’s Oseltamivir Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales revenue of Rituximab in the Chinese market in 2016-2019 has an increase trend. The sales revenue of Rituximab in China increases from CNY943 million in 2016 to CNY1.42 billion in 2019. The sales value of Rituximab in China was approximately CNY1.3 billion in 2020. It decreased 8.4% Year on Year. The reason for the sales decline is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Rituximab in China is 8.4% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Rituximab will have a recovery growth from 2021 to 2025. In addition, the sales will also increase due to the market expansion. Compared to indications approved in some developed countries, Rituximab has fewer indications being approved in China. The only two approved indications are non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Thus, the possibility of increase number of indications may bring new target patients for Rituximab. Besides, with the emergence of biosimilar drugs, Roche was no longer the monopoly in the Chinese Rituximab market. As a result, the price of Rituximab will be more affordable in the future, which will lead to an increase in sales volume.

Topics Covered:
-The impact of COVID-19 on China’s Rituximab market
– Sales value and volume of China’s Rituximab 2016-2020
– Competitive landscape of China’s Rituximab market
– Prices of Rituximab in China
– Prices of Rituximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Rituximab market
– Prospect of China’s Rituximab market from 2021 to 2025

The post Investigation Report on China’s Rituximab Market 2021-2025 first appeared on CRI Report.

Topics Covered:
-The impact of COVID-19 on China’s Tacrolimus market
– Sales value and volume of China’s Tacrolimus 2016-2020
– Competitive landscape of China’s Tacrolimus market
– Prices of Tacrolimus in China
– Prices of Tacrolimus in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Tacrolimus market
– Prospect of China’s Tacrolimus market from 2021 to 2025

The post Investigation Report on China’s Tacrolimus Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY 110 million in 2020. The annual growth rate in 2020 was 105.1%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of Aflibercept in China is 264% in 2018 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2021 to 2025. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME. However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low. The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.

Topics Covered:
-The impact of COVID-19 on China’s aflibercept market
– Sales value and volume of China’s aflibercept 2016-2020
– Competitive landscape of China’s aflibercept market
– Prices of aflibercept in China
– Prices of aflibercept in China by regions and manufacturers
– Analysis on factors affecting the development of China’s aflibercept market
– Prospect of China’s aflibercept market from 2021 to 2025

The post Investigation Report on China’s Aflibercept Market 2021-2025 first appeared on CRI Report.

Due to the high demand for HSA in the Chinese market, it has become one of the blood products that China allows to import from restricted countries. Currently, there are over 30 manufacturers in the Chinese HSA market. The major manufacturers are Grifols, Baxter, CSL Behring, Aventis Behring, and Shandong Taibang. Among them, Grifols accounts for the largest market share. In 2020, it took about 22.57% of the total market sales.

According to CRI’s market research, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020. In 2020, the annual growth rate was 11.3%, which slowed down compared to that in 2019 due to the COVID-19 epidemic. The CAGR of sales value of Human Serum Albumin in China is 9.3% in 2016 to 2020. CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of HSA will have a recovery growth from 2021 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Human Serum Albumin market
– Sales value and volume of China’s Human Serum Albumin 2016-2020
– Competitive landscape of China’s Human Serum Albumin market
– Prices of Human Serum Albumin in China
– Prices of Human Serum Albumin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Human Serum Albumin market
– Prospect of China’s Human Serum Albumin market from 2021 to 2025

The post Investigation Report on China’s Human Serum Albumin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Ibrutinib entered the Chinese market, the sales value of Ibrutinib in China has increased from CNY48,600 in 2017 to CNY 345.5 million in 2020. In 2020, the growth rate was 38.2%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of Ibrutinib in China is 1823% in 2017 to 2020%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Ibrutinib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to price reduction and market expansion. Currently, Ibrutinib has three approved indications. In 2020, the latest approved indication was included in the national medical insurance catalog, while the other two had been included in the catalog in 2018. As all indications can take advantage of the insurance reimbursement, the usage rate of Ibrutinib will increase among the patients. Moreover, with the emergence of other BTK inhibitor drugs, the price of Ibrutinib may continue to decrease, which will lead to a rise in sales. On the other hand, China approves fewer indications for Ibrutinib than other countries do. Therefore, the number of approved indications has the potential to increase, which means the market will keep expanding in the future.

Topics Covered:
-The impact of COVID-19 on China’s Ibrutinib market
– Sales value and volume of China’s Ibrutinib 2016-2020
– Competitive landscape of China’s Ibrutinib market
– Prices of Ibrutinib in China
– Prices of Ibrutinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Ibrutinib market
– Prospect of China’s Ibrutinib market from 2021 to 2025

The post Investigation Report on China’s Ibrutinib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. Th sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY. The growth rate slowed down last year is because the COVID-19 epidemic causes a reduction in the number of operations in hospitals, which influences the sales of Iodixanol. The CAGR of sales value of Iodixanol in China is 27% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved, the sales of Iodixanol will have a recovery growth from 2021 to 2025. In addition, the sales of Iodixanol will also increase due to the market expansion. According to the research, the sales of contrast agents are directly related to the holding volume of CT and MRI. The holding volume in China is much less than that in developed countries. For example, the holding volume of CT for a million people in China is 1/2 of that in the U.S., and 1/5 of that in Japan. Therefore, the number of equipment still has the potential to increase, which will lead the contrast agent market to expand. Iodixanol, as one of the most popular contrast agents, will continue to grow in the short term.

Topics Covered:
-The impact of COVID-19 on China’s Iodixanol market
– Sales value and volume of China’s Iodixanol 2016-2020
– Competitive landscape of China’s Iodixanol market
– Prices of Iodixanol in China
– Prices of Iodixanol in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Iodixanol market
– Prospect of China’s Iodixanol market from 2021 to 2025

The post Investigation Report on China’s Iodixanol Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales revenue of Lenalidomide in the Chinese market has an increasing trend from 2016 to 2020. Especially after Lenalidomide was included in the national medical insurance catalog in the second half of 2017, the annual growth rate in 2018 reached 547.4%. In 2020, the annual growth rate slowed down due to the COVID-19 epidemic, which affected the overall hospital operation. The sales value of Lenalidomide was CNY297.4 million in 2020 and the CAGR of Lenalidomide from 2016 to 2020 is 98.7% in China.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Lenalidomide will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to price reduction and market expansion. In recent years, with the emergence of generic drugs, the price of Lenalidomide has kept decreasing, which increases the usage rate of Lenalidomide among Chinese patients. At the same time, Lenalidomide applied for its third indication in China in March 2021. As the number of approved indications increases in China, the sales will continue to grow.

Topics Covered:
-The impact of COVID-19 on China’s Lenalidomide market
– Sales value and volume of China’s Lenalidomide 2016-2020
– Competitive landscape of China’s Lenalidomide market
– Prices of Lenalidomide in China
– Prices of Lenalidomide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Lenalidomide market
– Prospect of China’s Lenalidomide market from 2021 to 2025

The post Investigation Report on China’s Lenalidomide Market 2021-2025 first appeared on CRI Report.